NCT05773196 · RECRUITING
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
This study collects blood samples from people already diagnosed with Huntington's Disease. Researchers want to validate a genetic test that measures CAG repeat counts — the DNA mutation that causes Huntington's — and to build a biobank for future research into disease biomarkers. There is no treatment or drug involved. The phase is unspecified, meaning this is a observational collection effort, not a clinical intervention trial.
Eligibility criteria
Cohort 1: Huntington's Disease Inclusion: 1. The participant is willing and able to provide written informed consent 2. The participant is willing and able to provide appropriate photo identification 3. Participants aged 25 to 65, inclusive 4. Participants have been diagnosed with Huntington's Disease 5. Patients must have numerical documentation of CAG repeats present in the Medical Record, along with a Huntington's Disease diagnosis. 6. Pre-existing evidence of CAG repeats should be in the range of 40-60 repeats *Preference (not required for enrollment): Patients to have different CAG repeats from each other but this is not essential.* Exclusion: 1. Participants who are pregnant or are nursing 2. Participants with a known history of HIV, hepatitis, or other infectious diseases 3. Participants who have taken an investigational product in the last 30 days 4. Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-04-18